Sematrinity for Weight Loss in India: Does It Work?

The semaglutide patent expired in India on March 20, 2026, and generic brands launched from the next day. Among the many brands entering the market, Sun Pharma launched Sematrinity on March 21, 2026, and for anyone with obesity or type 2 diabetes in India, the weight loss question is the most important one to answer clearly.

Does it work? Here is the honest picture.

What is Sematrinity?

Sematrinity is Sun Pharma's generic version of semaglutide, the active molecule in Ozempic and Wegovy. It is a once-weekly subcutaneous injection that works as a GLP-1 receptor agonist: mimicking the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin response.

Sun Pharma launched it on March 21, 2026, the day after the patent expired.

Sun Pharma has separated its semaglutide brands:

• Sematrinity: for adults with insufficiently controlled type 2 diabetes (2 mg/1.5 mL and 4 mg/3 mL pens)
• Noveltreat: for chronic weight management in adults (five strengths from 0.25 mg to 2.4 mg, matching Wegovy dosing)

Sematrinity is not approved as a weight-loss medicine. If your primary goal is weight loss rather than diabetes management, Noveltreat is the relevant Sun Pharma brand to discuss with your doctor.

How does it promote weight loss?

Semaglutide produces weight loss through several mechanisms.

Appetite suppression. GLP-1 receptors in the hypothalamus (brain's appetite centre) receive signals that reduce hunger and food cravings. Most people experience a significant reduction in appetite, particularly for high-calorie foods.

Slower gastric emptying. Food stays in the stomach longer, extending the sensation of fullness after smaller meals.

Reduced calorie intake. The combined effect is that many people naturally eat less.

Improved insulin sensitivity. This reduces metabolic dysfunction that contributes to weight gain in people with type 2 diabetes or prediabetes.

What the trials show: the key numbers

Semaglutide's weight loss evidence is extensive. The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most relevant. Note that the STEP trials used the 2.4 mg weight-management dose (the Noveltreat and Wegovy dose), not the diabetes doses used with Sematrinity.

STEP 1 - Obesity without diabetes

• 68 weeks, 1,961 adults
• Semaglutide 2.4 mg: average 14.9% weight loss (~15.3 kg)
• Placebo: 2.4% weight loss
• 86% of participants lost at least 5% of body weight vs 32% on placebo

STEP 2 - Obesity + type 2 diabetes

• 68 weeks
• Semaglutide 2.4 mg: 9.6% average weight loss
• Placebo: 3.4%

Long-term data

Studies following participants for up to 4 years show maintained weight loss with continued use. Stopping the medication typically leads to weight regain, semaglutide treats obesity as an ongoing condition, not a one-time intervention.

Sematrinity vs Ozempic: is it truly the same?

Generic semaglutide brands contain the same active ingredient as the originator. Each brand needs approval from Indian regulators (the DCGI/CDSCO), and several Indian manufacturers have reported Phase 3 trials in Indian patients to support their approvals.

In practice: Sematrinity contains the same semaglutide molecule as Ozempic and is given once a week, so it is expected to have similar effects at the same dose. Both are used in India for type 2 diabetes. The pens differ, so do not switch brands without your doctor.

Pricing breakdown

Weekly ranges run from the starting dose to the highest dose, as stated by the companies at launch. Prices change, so check the current price with your pharmacy.

Who is it for?

Sematrinity (diabetes indication) is appropriate for adults with:

• Type 2 diabetes not adequately controlled by oral medication alone
• Overweight or obesity alongside their diabetes diagnosis

Noveltreat (weight management indication) is appropriate for adults with:

• Obesity, or overweight with weight-related health problems, as set out in the Indian label and assessed by your doctor (the STEP trials enrolled people with a BMI of 30 or more, or 27 or more with a weight-related condition); a diabetes diagnosis is not required
• Those who previously could not afford imported semaglutide for weight management

Side effects to expect

Side effects are identical to those of Ozempic and Wegovy, because the molecule is identical.

Most common:

• Nausea, usually worst in the first weeks and after dose increases, then improving
• Vomiting, diarrhoea or constipation
• Abdominal discomfort
• Fatigue or dizziness in early weeks

These are more frequent at higher doses.

The standard semaglutide warnings apply:

• Thyroid C-cell tumours (a boxed warning in the US label): do not use if you or a family member has had medullary thyroid carcinoma, or you have MEN2 syndrome
• Pancreatitis: seek urgent medical help for severe stomach pain that does not go away, which may spread to your back
• Gallbladder problems: pain in the upper right abdomen, fever or yellowing of the skin or eyes
• Dehydration and kidney problems: get help if you cannot keep fluids down
• Low blood sugar: more likely if you also take insulin or a sulfonylurea; your doctor may adjust those medicines
• Eye changes: report any change in vision, especially if you have diabetic eye disease
• Serious allergic reactions: seek emergency help for swelling of the face or throat or trouble breathing
• Pregnancy and surgery: semaglutide is not used in pregnancy; tell your doctor or anaesthetist you take it before surgery or sedation

Practical tips for Indian patients

Start low, go slow. Semaglutide usually starts at 0.25 mg once a week for the first 4 weeks, and your doctor decides each increase. Rushing the titration increases GI side effects significantly, so never change your dose yourself.

Protein first. Indian diets can be lower in protein than optimal during rapid weight loss. Prioritise dal, paneer, Greek yoghurt, eggs, and legumes to maintain muscle and reduce hair thinning risk.

Track your doses. Missing a weekly injection or losing track of where you are in the titration is common without a system. Weight Easy supports semaglutide tracking for Indian users.

Buy from licensed sources only. Counterfeit GLP-1 pens are a documented issue. Purchase only from registered pharmacies, 1mg, Netmeds, PharmEasy, or directly from hospital pharmacies.

Combine with lifestyle changes. The trial data showing 15% weight loss was achieved with a 500-calorie deficit diet and 150 minutes of weekly exercise. Medication alone, without lifestyle change, produces significantly smaller results.

What does this mean for India's obesity market?

An estimated 101 million people in India live with diabetes (ICMR-INDIAB study, 2023), and almost one in four Indians aged 15 to 49 is overweight or obese (NFHS-5). Until recently, GLP-1 therapy was largely inaccessible due to cost: branded semaglutide cost more than ₹10,000 a month before generics arrived.

Generic semaglutide priced from a few thousand rupees a month changes the calculation for many patients.

Final takeaway

Sematrinity contains the same semaglutide as Ozempic, launched in India on March 21, 2026, at a lower price than the originator. It is approved for type 2 diabetes, where it improves blood sugar control and often leads to some weight loss. The average 15% weight loss over 68 weeks seen in STEP 1 came from the 2.4 mg weight-management dose (Sun Pharma's Noveltreat). If you have type 2 diabetes or obesity in India, this is now a realistic and accessible conversation to have with your endocrinologist.

Always consult your healthcare provider before starting any medication. Results vary by individual.

Consult your healthcare provider before starting any medication.

Sources

• Sun Pharma launch press release for Noveltreat and Sematrinity, March 21, 2026: https://sunpharma.com/wp-content/uploads/2026/03/SEintimationPRforSemaglutide.pdf
• STEP 1 trial (NEJM, 2021): https://pubmed.ncbi.nlm.nih.gov/33567185/
• STEP 2 trial (Lancet, 2021): https://pubmed.ncbi.nlm.nih.gov/33667417/
• Ozempic India launch and prices (The National, December 12, 2025): https://www.thenationalnews.com/health/2025/12/12/ozempic-india-weight-loss-drug/
• Novo Nordisk India price cut (Business Today, March 31, 2026): https://www.businesstoday.in/amp/industry/pharma/story/novo-further-cuts-semaglutide-prices-as-generics-enter-india-523336-2026-03-31/
• Generic semaglutide prices in India (South First): https://thesouthfirst.com/health/generic-semaglutide-launches-in-india-after-patent-expiry-prices-drop-sharply/
• Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in/opencms/opencms/en/Home/
• MedicalDialogues — India semaglutide market and brand launch context: https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• WHO — obesity and overweight: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight